EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prognostic Value of C-Reactive Protein to Albumin Ratio in Glioblastoma Multiforme Patients Treated with Concurrent Radiotherapy and Temozolomide

Erkan Topkan iD, Ali A Besen iD, Huseyin Mertsoylu iD, Ahmet Kucuk iD, Berrin Pehlivan, Ugur Selek iD

International Journal of Inflammation · 08.06.2020 · 2020 · 1-8

DOI: 10.1155/2020/6947382 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Inflammation, erschienen am 08.06.2020. Verfasst von Erkan Topkan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Baskent University Medical Faculty, Department of Radiation Oncology, Adana, Turkey. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

We investigated the prognostic impact of C-reactive protein to albumin ratio (CRP/Alb) on the survival outcomes of newly diagnosed glioblastoma multiforme (GBM) patients treated with radiotherapy (RT) and concurrent plus adjuvant temozolomide (TMZ).

Methods

The pretreatment CRP and Alb records of GBM patients who underwent RT and concurrent plus adjuvant TMZ were retrospectively analyzed. The CRP/Alb was calculated by dividing serum CRP level by serum Alb level obtained prior to RT. The availability of significant cutoff value for CRP/Alb that interacts with survival was assessed with the receiver-operating characteristic (ROC) curve analysis. The primary endpoint was the association between the CRP/Alb and the overall survival (OS).

Results

A total of 153 patients were analyzed. At a median follow-up of 14.7 months, median and 5-year OS rates were 16.2 months (95% CI: 12.5–19.7) and 9.5%, respectively, for the entire cohort. The ROC curve analysis identified a significant cutoff value at 0.75 point (area under the curve: 74.9%; sensitivity: 70.9%; specificity: 67.7%; P < 0.001 ) for CRP/Alb that interacts with OS and grouped the patients into two: CRP/Alb

Autor:innen und Institutionen

  • Baskent University Medical Faculty, Department of Radiation Oncology, Adana, Turkey.
  • Baskent University Medical Faculty, Department of Medical Oncology, Adana, Turkey.
  • Mersin City Hospital, Radiation Oncology Clinics, Mersin, Turkey.
  • Department of Radiation Oncology, Bahcesehir University, Goztepe, Istanbul, Turkey.
  • Koc University, School of Medicine, Department of Radiation Oncology, Istanbul, Turkey.
  • The University of Texas, MD Anderson Cancer Center, Department of Radiation Oncology, Houston, TX, USA.

ORCID-Profile: Erkan Topkan, Ali A Besen, Huseyin Mertsoylu, Ahmet Kucuk, Ugur Selek

Zitieren

APA

Topkan, E., Besen, A. A., Mertsoylu, H., Kucuk, A., Pehlivan, B., & Selek, U. (2020). Prognostic Value of C-Reactive Protein to Albumin Ratio in Glioblastoma Multiforme Patients Treated with Concurrent Radiotherapy and Temozolomide. International Journal of Inflammation, 2020, 1-8. https://doi.org/10.1155/2020/6947382

Vancouver

Topkan E, Besen AA, Mertsoylu H, Kucuk A, Pehlivan B, Selek U. Prognostic Value of C-Reactive Protein to Albumin Ratio in Glioblastoma Multiforme Patients Treated with Concurrent Radiotherapy and Temozolomide. International Journal of Inflammation. 2020;2020:1-8. doi:10.1155/2020/6947382

BibTeX
@article{Topkan2020,
  author = {Topkan, Erkan and Besen, Ali A and Mertsoylu, Huseyin and Kucuk, Ahmet and Pehlivan, Berrin and Selek, Ugur},
  title = {Prognostic Value of C-Reactive Protein to Albumin Ratio in Glioblastoma Multiforme Patients Treated with Concurrent Radiotherapy and Temozolomide},
  journal = {International Journal of Inflammation},
  year = {2020},
  volume = {2020},
  pages = {1--8},
  doi = {10.1155/2020/6947382}
}
Kostenlos starten →